RxDoctor Payments Data

Steffani Letchworth

Adult Health · Greenville, NCNPI 1841668720

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,750 of the $7,741 with a category attached, or 61.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 65.6% of it on its own, with 12 other manufacturers making up the rest. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,741in general payments, 2019–2025

Across 229 payments — averaging $33.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AstraZeneca$496
  • Novartis$344
  • Amgen$263
  • Johnson & Johnson$121
  • plus $287 from 7 others

What the payments were for

  • Speaking & faculty fees$4,75061%
  • Food & beverage$2,97238%
  • Education$180%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,741 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$139,132
Medicare patients
666
Services billed
3,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$465,063
EntrestoSacubitril/Valsartan135$110,195
Repatha SureclickEvolocumab138$104,061
XareltoRivaroxaban101$74,732
FarxigaDapagliflozin Propanediol61$44,016
JardianceEmpagliflozin32$31,400
BrilintaTicagrelor47$25,523
MultaqDronedarone Hcl18$21,159
Ranolazine ErRanolazine121$9,734
Metoprolol Succinate435$4,311
Bumetanide121$3,868
Potassium Chloride130$2,899
Atorvastatin Calcium270$2,769
Midodrine Hcl54$2,459
Rosuvastatin Calcium189$2,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$465,063589 claims
NovartisEntresto$344$110,195135 claims
Johnson & JohnsonXarelto$121$74,732101 claims
AstraZenecaFarxiga, Brilinta$496$69,539108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.

Other adult health in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →